University of Ottawa, Faculty of Medicine, Public Health Genomics
Date Written: November 1, 2013
Abstract
The cost of whole genome sequencing is dropping rapidly. There has been a great deal of enthusiasm about the potential for this technological advance to transform clinical care. Given the interest and significant investment in genomics, this seems an ideal time to consider what the evidence tells us about potential benefits and harms, particularly in the context of health care policy. The scale and pace of adoption of this powerful new technology should be driven by clinical need, clinical evidence, and a commitment to put patients at the centre of health care policy.
Caulfield, Timothy and Evans, James P. and McGuire, Amy L. and McCabe, Christopher and Bubela, Tania and Cook-Deegan, Robert M and Fishman, Jennifer and Hogarth, Stuart and Miller, Fiona A. and Ravitsky, Vardit and Biesecker, Barbara and Borry, Pascal and Cho, Mildred K. and Carroll, June and Etchegary, Holly and Joly, Yann and Kato, Kazuto and Lee, Sandra and Rothenberg, Karen H. and Sankar, Pamela and Szego, Michael and Ossorio, Pilar and Pullman, Daryl and Rousseau, Francois and Ungar, Wendy and Wilson, Brenda, Reflections on the Cost of 'Low Cost' Whole Genome Sequencing: Framing the Health Policy Debate (November 1, 2013). PLOS Biology, V. 11, No. 11, November 2013, p. e1001699, U of Maryland Legal Studies Research Paper No. 2013-68, Available at SSRN: https://ssrn.com/abstract=2351458
Subscribe to this fee journal for more curated articles on this topic
FOLLOWERS
51
PAPERS
3,018
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.
Download This Paper